Zanubrutinib
- Generic Name
- Zanubrutinib
- Brand Names
- Brukinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O3
- CAS Number
- 1691249-45-2
- Unique Ingredient Identifier
- AG9MHG098Z
- Background
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
- Indication
Zanubrutinib is indicated for the treatment of:
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
- Associated Therapies
- -
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 652
- Registration Number
- NCT03734016
- Locations
- 🇺🇸
Carti Cancer Center, Little Rock, Arkansas, United States
🇺🇸David Geffen School of Medicine At UCLA, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers Boulder, Boulder, Colorado, United States
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 41
- Registration Number
- NCT03520920
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 29
- Registration Number
- NCT03465059
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 590
- Registration Number
- NCT03336333
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 217
- Registration Number
- NCT03332017
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Illinois At Chicago, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 44
- Registration Number
- NCT03332173
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 86
- Registration Number
- NCT03206970
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 91
- Registration Number
- NCT03206918
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 44
- Registration Number
- NCT03189524
- Locations
- 🇨🇳
Tianjin Hematonosis Hospital, Tianjin, Tianjin, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 41
- Registration Number
- NCT03145064
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.